We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+9.63%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
-$122M
Cap. Flow
-$69.5M
Cap. Flow %
-4.44%
Top 10 Hldgs %
64.55%
Holding
66
New
15
Increased
13
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$46.2M
2
ISRG icon
Intuitive Surgical
ISRG
+$36.9M
3
BIIB icon
Biogen
BIIB
+$36.7M
4
MRK icon
Merck
MRK
+$25.7M
5
PTCT icon
PTC Therapeutics
PTCT
+$23.6M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$95.2M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$74.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$57.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$45.3M
5
AZN icon
AstraZeneca
AZN
+$41.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
51
Alnylam Pharmaceuticals
ALNY
$38.5B
$89.7K 0.01%
448
-56,000
-99% -$11.8M
AGEN
52
CALL
Agenus
AGEN
$275M
– –
-64,554
Closed -$3.04M
ALGN icon
53
Align Technology
ALGN
$12.6B
– –
-83,100
Closed -$17.5M
ALNY icon
54
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
– –
-100,000
Closed -$23.8M
AZN icon
55
AstraZeneca
AZN
$267B
– –
-306,837
Closed -$41.6M
CYTK icon
56
CALL
Cytokinetics
CYTK
$10.8B
– –
-100,000
Closed -$4.58M
FULC icon
57
Fulcrum Therapeutics
FULC
$248M
– –
-631,411
Closed -$4.6M
GERN icon
58
CALL
Geron
GERN
$930M
– –
-2,369,100
Closed -$5.73M
RCUS icon
59
Arcus Biosciences
RCUS
$3.4B
– –
-314,811
Closed -$6.51M
SNY icon
60
Sanofi
SNY
$109B
– –
-1,965,475
Closed -$95.2M
UTHR icon
61
United Therapeutics
UTHR
$26.1B
– –
-89,207
Closed -$24.8M
VRTX icon
62
Vertex Pharmaceuticals
VRTX
$124B
– –
-156,989
Closed -$45.3M
OBSV
63
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-4,749,623
Closed -$689K
CINC
64
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-6,073,949
Closed -$74.6M
CTIC
65
CALL
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-410,000
Closed -$2.46M
1 2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2023 Portfolio in Review

As of Q1 2023, Sofinnova Investments held 66 positions worth $1.56B, down 7.2% from $1.69B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sofinnova Investments withdrew a net $69.5M in Q1 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Sanofi, an estimated $95.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Eli Lilly worth $47.1M.

  • Sofinnova Investments's largest Q1 2023 buy was Eli Lilly: 137,100 shares worth $47.1M.
  • Sofinnova Investments added most to Merck in Q1 2023, an estimated $25.7M increase.
  • Sofinnova Investments's biggest Q1 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $57.4M.
  • Sofinnova Investments fully exited Sanofi in Q1 2023, selling an estimated $95.2M.
  • Sofinnova Investments's ten largest holdings make up 65% of its $1.56B portfolio in Q1 2023.
  • Sofinnova Investments opened 15 new positions and closed 14 in Q1 2023.
  • Sofinnova Investments's portfolio value fell 7.2% quarter-over-quarter to $1.56B.

Based on Sofinnova Investments's 13F filing for Q1 2023, filed 11 May 2023.